Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ovayoza Adeleye

Psychiatry Natchitoches, LA Medical Doctor

NPI 1538150263 CMS profile 251450

117 South Dr, Natchitoches, LA 71457

Open in the dashboard

General payments

$4,777

294 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ovayoza Adeleye of Natchitoches, LA is reported in the CMS Open Payments database as having received $4,777 across 294 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,099 60
2024 General $629 41
2023 General $908 66
2022 General $806 57
2021 General $981 61
2020 General $174 4
2019 General $180 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ovayoza Adeleye
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ovayoza Adeleye were reported at $1,099. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ovayoza Adeleye Psychiatry median Middle half National median
2019 $180 $184 $59–$605 $163
2020 $174 $119 $36–$372 $114
2021 $981 $143 $43–$576 $132
2022 $806 $153 $50–$590 $149
2023 $908 $170 $56–$651 $160
2024 $629 $179 $57–$673 $164
2025 $1,099 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $883 85 payments
  2. Teva Pharmaceuticals USA, Inc. $791 39 payments
  3. Alkermes, Inc. $583 35 payments
  4. Otsuka America Pharmaceutical, Inc. $436 25 payments
  5. Neurocrine Biosciences, Inc. $380 21 payments
  6. ITI, Inc. $354 22 payments
  7. Lundbeck LLC $294 15 payments
  8. Vanda Pharmaceuticals Inc. $202 9 payments
  9. Janssen Pharmaceuticals, Inc $149 9 payments
  10. Allergan Inc. $146 2 payments
  11. Other $559 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,623 291 payments
  2. Education $155 3 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $656 70 payments
  2. ARISTADA Cns $570 34 payments
  3. ARISTADA Cns $570 34 payments
  4. ARISTADA Cns $509 30 payments
  5. ARISTADA Cns $509 30 payments
  6. INGREZZA $380 21 payments
  7. VRAYLAR Neuroscience $374 17 payments
  8. ARISTADA INITIO $324 15 payments
  9. Austedo XR $321 18 payments
  10. LYBALVI $320 24 payments
  11. Other $2,841 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,455

Median for Psychiatry: 574

Drug cost

$629,072

Median for Psychiatry: $27,624

Branded share of claims

24.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 28 $328,321
Invega Sustenna Paliperidone Palmitate Brand 58 $167,963
Abilify Maintena Aripiprazole Brand 37 $74,073
Vraylar Cariprazine Hcl Brand 19 $29,291
Lurasidone Hcl Generic 33 $6,274
Clozapine Generic 15 $2,372
Aripiprazole Generic 68 $1,632
Quetiapine Fumarate Generic 89 $1,528
Bupropion Xl Bupropion Hcl Brand 55 $1,287
Duloxetine Hcl Generic 70 $1,198

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $153
$153 19 —
REXULTI
  • Lundbeck LLC $64
  • Otsuka America Pharmaceutical, Inc. $32
$96 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $75
$75 — —
ARISTADA
  • Alkermes, Inc. $58
$58 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $46
$46 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

294 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record